The primary role of this medication is to provide supportive symptomatic management for vascular conditions where symptoms interfere with daily functioning. This treatment is used in situations involving certain distressing symptoms across two main therapeutic domains.

Key Therapeutic Focus

The medication is commonly used to help address symptom clusters linked to organ-specific functional stress. This includes managing the daily sensation of leg heaviness, aching, and symptoms related to physical discomfort in Chronic Venous Insufficiency (CVI). In contexts involving acute hemorrhoids, it is applied when additional symptomatic support is needed for challenging manifestations such as localized pain, severe discomfort, and associated bleeding.

“The primary goal of this therapy is to ease the overall symptom load and support general well-being during symptomatic phases.”

The treatment may assist with maintaining functional stability and supports the management of swelling and functional discomfort in the lower limbs, which is relevant in conditions characterized by periods of heightened symptoms.

---

Quick Fact: Relief for Venous Discomfort

Focus	Symptom	Benefit
Chronic	Leg heaviness and aching	Helps improve day-to-day comfort during symptomatic periods
Acute	Anorectal pain and discomfort	Supports patients during difficult episodes by easing distress
Functional	Lower-limb swelling (Edema)	Assists with maintaining functional stability

Regulatory References

1. Health Canada product information

Official Eligibility Profile: Who Can and Cannot Use Детралекс

The regulatory status of this medicine defines specific populations who are restricted from use or for whom use is not recommended.

Contraindications (Must Not Use)

Use is strictly contraindicated for any individual with a documented history of hypersensitivity or allergy to the active substance, which is the Micronized Purified Flavonoid Fraction (Diosmin and Hesperidin), or to any of the product's inactive components (excipients).

Age-Based and Conditional Restrictions

Population Group	Official Eligibility Status
Adults (18 years and older)	Approved population for established use.
Children and Adolescents (Under 18)	Use not recommended; safety and efficacy not established.
Pregnant Women	Preferable to be avoided as a precautionary measure.
Breastfeeding Women	Use is inadvisable or not recommended (excretion into human milk is unknown).
Acute Hemorrhoidal Attack	Use is restricted to short-term symptomatic relief only.

For the adult population, the medicine is restricted to established uses. No specific restrictions related to renal or hepatic impairment are formally documented in the official eligibility sections of the regulatory documents.

Interactions with other medicines and products

The official regulatory profile for Детралекс (Micronized Purified Flavonoid Fraction) defines its interaction status primarily by the absence of specific, documented findings from interaction studies. All information in this section is based strictly on the Summary of Product Characteristics (SmPC) and equivalent government prescribing information.

Documented Interaction Status

Interaction Category	Regulatory Finding
Specific Drug-Drug Interactions	None documented. The official regulatory label does not list any specific medicinal products that are contraindicated or restricted due to known interaction risk.
Metabolic/Transporter Mechanisms	None documented. Regulatory documents state that no specific studies investigating interactions mediated by metabolic enzymes (e.g., CYP pathways) or drug transporters have been performed.
Contraindicated Combinations	None documented. The regulatory profile does not contain a list of formally prohibited combinations or specific substances that must not be co-administered.

Interactions with Food and Other Substances

The official product information does not list any specific interactions with alcohol, herbal products, or dietary supplements.

The only constraint related to co-administration is a timing-based administration rule: the product is officially recommended to be taken at meal time (with food). This timing instruction is a standard condition of use documented in the regulatory text.

Interaction Profile Summary The overall interaction profile is characterized by the official regulatory statement that no cases of drug interaction have been reported since the product’s marketing authorization. Patients are always advised to inform a healthcare provider about all medicines and products being taken concomitantly.

Modulating Vascular Tone and Permeability

This domain involves the compound's influence on the microcirculation, specifically the pathways that govern the constriction and dilation of blood vessels (vascular tone) and the integrity of the vessel walls (permeability). The compound exhibits an influence on the magnitude of fluid efflux and modulates the degree of abnormal vasodilation, facilitating pathway adjustment within the microcirculation.

Regulating Inflammatory Mediator Release

The compound engages mechanisms that influence the release and activity of key chemical mediators and transmitters. The compound alters early molecular steps, influencing the concentration and subsequent pathway signaling of inflammatory mediators. This engagement dictates the downstream physiological responses.

Enhancing Lymphatic Drainage Mechanisms

This cluster highlights the compound's role in systems where targeted pathway adjustment is required to affect the mobilization of interstitial fluid. The compound facilitates the functional capacity of the lymphatic system by engaging signaling patterns that modulate drainage efficiency. This activity affects the mobilization of interstitial fluid.

The administration of the Micronized Purified Flavonoid Fraction (MPFF) formulation is based on specific administration parameters. The medicine is restricted to the oral route of administration and is available as a 500 mg film-coated tablet or, in some regions, a 1000 mg oral suspension in a sachet.

Standard Administration Principles

The medication is taken at meal times, with tablets swallowed whole with a glass of water. Dosing regimens are structured around the specific condition being addressed:

Context of Use	Daily Dose Amount (MPFF)	Frequency and Duration
Venolymphatic Insufficiency	1000 mg	Two divided doses daily (or once daily for 1000 mg forms)
Acute Hemorrhoids	Tapered over 7 days	Begins at 3000 mg daily for 4 days, followed by 2000 mg daily for 3 days

Procedural and Population-Specific Rules

For the acute hemorrhoidal regimen, the use is a fixed, short-term course; if symptoms persist beyond 15 days, the treatment requires re-evaluation. If a dose is forgotten, the protocol involves taking the next dose at the usual time rather than doubling a dose to compensate for the missed one. Furthermore, the safety and efficacy of the medication have not been established in the pediatric population (under 18 years of age).

These requirements include specific timing with food, fixed-duration courses, and population-specific restrictions for the use of the medication.

Research Evidence / Overview of Studies

Phase 3 Clinical Trials

Research has explored whether the drug may be associated with a modification in the severity of symptoms in adults with chronic venous disease (CVD). Studies often focused on cohorts of participants followed over short-to-medium durations, typically up to two months.

The main randomized controlled trials (RCTs) involving the micronized purified flavonoid fraction (MPFF) indicated that the group receiving the drug showed findings suggesting a potential association with a change in the duration and severity of symptoms, such as heaviness and pain, compared to the placebo group. Studies also evaluated outcomes when this formulation was used in combination with other therapeutic approaches.

---

Tolerability Profile

Multiple small-scale studies examined a potential association with relief from symptoms, including headache and general discomfort related to CVD. The results indicated that the active drug demonstrated a defined tolerability profile, with the most common reported side effects being mild gastrointestinal disturbances (e.g., nausea, diarrhea) and headache.

Further research was conducted to assess the drug’s use in older populations, including people over 65. These studies included participants to examine the tolerability and reported a comparable incidence of adverse events to the younger study population, provided there were no major pre-existing complications.

---

Ongoing Research

Several trials are underway to investigate the effects in different disease stages or populations. For instance, open-label studies have been investigating whether there was a relationship with a reduction in pain and fever in certain pediatric populations.

The inclusion criteria for the majority of the studies have excluded people with severe complications such as renal impairment or severe cardiovascular disease, suggesting that the research to date is focused on otherwise healthy participants with venous symptoms.

Key Studies & References

1. The place of micronized purified flavonoid fraction in the management of chronic venous disease from an international guidelines' perspective

Common questions about Детралекс (FAQ)

Q: Is Детралекс a blood thinner or is it something different?

A: Детралекс is officially classified as a phlebotonic and vascular protector. Its mechanism of action is to support the strength and function of the veins and capillaries. This pharmacological approach is distinct from that of conventional anticoagulant medicines, which are commonly known as 'blood thinners'.

Q: Does Детралекс interact negatively with common pain relievers like ibuprofen?

A: Official regulatory documents do not list any specific documented drug-drug interactions with common pain relievers. Regulatory advice emphasizes that patients should always inform a healthcare provider about all medicines being taken concurrently.

Q: Is it normal to feel a slight stomach upset when starting Детралекс?

A: Mild gastrointestinal disturbances are listed as common side effects in regulatory documents, with reactions like diarrhea, indigestion, nausea, and vomiting noted. These reactions are among the most frequently reported during treatment, according to the official safety profile.

Q: What are the most common side effects of Детралекс reported by users?

A: According to official regulatory data, the most common side effects (affecting 1 to 10 users in 100) are mild issues that affect the digestive system. These include diarrhea, indigestion (dyspepsia), nausea, and vomiting.

Q: Are there any specific foods or drinks to avoid while using Детралекс?

A: Official product information does not list any specific foods, drinks, or alcohol that must be avoided while using this medicine. The only instruction regarding consumption is the standard regulatory requirement that the medicine should be taken at meal time (with food).

Q: Can taking Детралекс cause headaches or dizziness?

A: Yes, headache and dizziness are reported as potential side effects. These are listed as Rare reactions, meaning they affect only 1 to 10 users in 10,000, according to regulatory documentation.

Q: Does taking Детралекс interact with birth control pills?

A: Official regulatory documents do not list any specific documented interaction between Детралекс and oral contraceptives (birth control pills). Regulatory advice emphasizes that patients should inform a healthcare provider about all medicines being taken.

Q: Is it safe to take vitamins or multivitamins while on Детралекс?

A: Although official product information does not list specific interactions with general dietary supplements or vitamins, patients are advised to consult with a healthcare provider before combining any supplements with this medication.

Q: Does Детралекс help with swelling or just pain in the legs?

A: The general purpose is to help mitigate symptoms like heaviness and discomfort resulting from impaired venous function. Pharmacologically, the compound is noted to influence fluid efflux and enhance lymphatic drainage mechanisms, which are actions related to reducing swelling (edema).

Q: Is the benefit of Детралекс proven for preventing varicose veins?

A: Official research evidence has centered on evaluating its effects on modifying the severity of existing symptoms, such as heaviness and pain, in adults with chronic venous disease. Regulatory documents do not state an indication for preventing the initial formation of varicose veins.

Q: Is it okay for older adults (70+) to take Детралекс?

A: The official eligibility profile defines the approved population as adults aged 18 years and older. Studies including people over 65 years reported that the tolerability profile and incidence of adverse events were comparable to younger adults, provided the patient did not have major pre-existing complications.

Q: Are there special considerations for taking Детралекс if I have kidney issues?

A: While official regulatory documents do not formally list restrictions related to kidney function, the majority of clinical studies to date have excluded individuals with severe renal impairment. Consultation with a healthcare provider is essential due to the limited research in this specific group.

Q: Can I combine Детралекс with compression stockings for better results?

A: Clinical research has evaluated the outcomes when this medicine was used in combination with other therapeutic approaches. For chronic venous conditions, combining medical treatments with non-medical methods, like wearing compression stockings, is often considered a standard part of overall management.

Q: Does the time of day I take Детралекс matter for its effectiveness?

A: The official protocol requires the medication to be taken at meal times. The specific time of day (e.g., morning versus evening) is not explicitly mandated in regulatory instructions, but consistency with meal consumption is required for proper administration.

Q: Can Детралекс make existing allergies worse?

A: Use of the medicine is strictly contraindicated if there is a documented history of hypersensitivity or allergy to the active substance or to any of the product's inactive components. Patients with known allergies are advised to discuss them with a healthcare professional.

Q: Does Детралекс interact with common acid reflux medications?

A: Official regulatory documents do not list any specific documented interaction between this medicine and common acid reflux medications. It is always advised to discuss the full medication list with a healthcare provider before starting treatment.

Q: Does Детралекс have any reported effects on mood or sleep?

A: Official regulatory documents list adverse reactions related to the nervous system, such as malaise (a general feeling of discomfort) and dizziness, as Rare side effects. No direct effects on mood or sleep are specifically listed in the product's safety information.

Q: What are the signs of a rare but serious side effect from Детралекс?

A: The most significant safety concern listed in regulatory documents is a severe hypersensitivity reaction, such as angioedema. This is characterized by rapid swelling of tissues, including the face, lips, mouth, tongue, or throat. In such cases, official regulatory documents indicate that the medicine must be stopped immediately.

Q: Are there any known interactions between Детралекс and alcohol?

A: Official product information does not list any specific interactions with alcohol. However, patients are generally advised to consult with a healthcare professional regarding the consumption of alcohol while on medication.

Q: Is it okay to crush or chew the Детралекс tablet?

A: No. The official instructions for administering the film-coated tablets emphasize that they must be swallowed whole with a glass of water. They are not intended to be crushed or chewed.

Q: Can Детралекс be used in combination with topical creams for veins?

A: Clinical research has evaluated outcomes when the drug was used in combination with other therapeutic approaches for venous symptoms. Patients are advised to consult their healthcare provider to discuss the appropriate combination of treatments for their specific condition.

Official Storage and Disposal Requirements

The storage and disposal instructions for Детралекс tablets are strictly defined in the official regulatory documents to maintain product quality and safety.

Storage Conditions

Requirement	Official Statement
Temperature	Store below 25 C (or not above 30 C).
Protection	Store in the original package.
Prohibited	Do not refrigerate or freeze.

Handling and Safety

• The medication must be kept out of the sight and reach of children at all times.
• Storing the product in its original packaging protects the tablets from moisture and light, which is necessary for maintaining their stability.

Disposal Instructions

• Unused or expired tablets and any waste material must be disposed of according to local requirements for pharmaceutical waste.
• The medicine should not be disposed of via wastewater or household waste to prevent environmental contamination.